Case Details
- Citation: [2016] SGHC 106
- Case Title: Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd
- Court: High Court of the Republic of Singapore
- Suit No: 390 of 2015
- Summons No: 4136 of 2015
- Date of Judgment: 26 May 2016
- Date Judgment Reserved: 23 November 2015
- Judge: George Wei J
- Plaintiff/Applicant: Warner-Lambert Company LLC
- Defendant/Respondent: Novartis (Singapore) Pte Ltd
- Legal Area: Patents and Inventions (pharmaceutical patent; amendments; novelty)
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed) (including ss 83(1), 84(3), 25(5), 36, 38); Medicines Act (Cap 176, 1985 Rev Ed) (s 12A(3)(a)); Rules of Court (O 87A r 11(1))
- Other Jurisdictional Reference: UK Patents Act 1977 (notably s 75) (as comparative context)
- Cases Cited (as referenced in the extract): [2016] SGHC 106 (self-citation in metadata); Trek Technology (Singapore) Pte Ltd v FE Global Electronics Pte Ltd and other suits [2005] 3 SLR(R) 389; Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd and others and another suit [2015] 4 SLR 781; Smith Kline & French Laboratories v Evans Medical Limited [1989] FSR 561; FE Global (HC) [2005] 3 SLR(R) 389; CIPA Guide to the Patents Act (Paul G Cole gen ed) (Sweet & Maxwell, 7th Ed, 2011); Terrell on the Law of Patents (Richard Miller et al) (Sweet & Maxwell, 17th Ed, 2010)
- Judgment Length: 60 pages; 18,576 words
Summary
Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd concerned an application to amend a Singapore pharmaceutical patent during ongoing proceedings in which the defendant had challenged the patent’s validity. The plaintiff, the patent proprietor, sought leave to amend its claims under s 83(1) of the Patents Act. The central practical purpose of the amendments was to respond to the defendant’s argument that the granted patent claimed an unpatentable “method of treatment” monopoly.
The High Court (George Wei J) dismissed the application for leave to amend. Although the court accepted that the amendment regime under s 83 is the proper procedural vehicle where validity is already in issue, it held that the proposed amendments could not be allowed because they ran into statutory constraints under s 84(3) of the Patents Act (including the prohibition on amendments that disclose additional matter or extend the protection conferred). The court also exercised its discretion against amendment, taking into account factors such as delay, the perceived attempt to obtain advantage from a patent that was “and always has been” invalid, and concerns about disclosure.
What Were the Facts of This Case?
The patent at the centre of the dispute claimed a monopoly over the use of pregabalin for the treatment of pain. The plaintiff manufactured and distributed “Lyrica”, a pregabalin-based product. Lyrica had been approved by Singapore’s Health Sciences Authority (HSA) for treating, among other conditions, neuropathic pain and chronic pain disorders, including fibromyalgia. The patent was filed on 16 July 1997 and granted in Singapore on 23 May 2000.
Because Singapore patents are protected for a term of 20 years from the filing date of the application (s 36 of the Patents Act), the patent was approaching the end of its term. The plaintiff also held corresponding patents in other jurisdictions, derived from an international application filed on 16 July 1997, including patents in Australia and Europe. This international context mattered because the plaintiff’s claim strategy and amendment proposals were framed against prior art and claim formats used elsewhere.
On 23 March 2015, the plaintiff received notice that the defendant had applied to the HSA for product licences relating to pregabalin products. The notice was made pursuant to s 12A(3)(a) of the Medicines Act. In the notice, the defendant alleged that the acts for which the product licences were sought would not infringe the plaintiff’s patent. In response, on 21 April 2015, the plaintiff commenced an action seeking, among other relief, a declaration that the defendant’s acts would infringe the patent.
After commencing the action, the plaintiff notified the defendant on 5 May 2015 that it intended to apply to amend the patent. The defendant then filed its defence and counterclaim, seeking revocation on the ground that the patent was and always had been invalid because it claimed a monopoly over methods of treatment of the human or animal body, which are not patentable in Singapore. The plaintiff advertised the proposed amendments on 29 June 2015 in accordance with O 87A r 11(1) of the Rules of Court, and the defendant opposed the amendments on 24 July 2015. On 26 August 2015, the plaintiff brought the present application to amend the claims.
What Were the Key Legal Issues?
The first key issue was procedural and logically anterior: whether, when deciding an application to amend under s 83(1), the court should consider the validity of the amended patent in the same way as it would for a full revocation challenge. The defendant argued that the amendments would be futile because the amended claims would still fail patentability requirements such as novelty, inventive step, and industrial application. The court had to decide whether it should “pre-judge” validity or whether the amendment stage should be approached differently.
The second issue concerned the statutory limits on amendments. Under s 84(3) of the Patents Act, amendments are prohibited if they would result in the specification disclosing additional matter or extending the protection conferred by the patent. The court therefore had to assess whether the proposed amendments complied with these constraints, including whether the amendments effectively broadened or altered the scope of the monopoly beyond what was originally disclosed.
The third issue was discretionary. Even if the amendments were not barred by s 84(3), the court had to decide whether it should exercise its discretion to allow the amendments. The defendant relied on factors including alleged unreasonable delay, the plaintiff’s alleged attempt to obtain an unfair advantage from a patent that it knew was invalid, and alleged failure to make full disclosure of relevant matters relating to the proposed amendments.
How Did the Court Analyse the Issues?
The court began by setting out the governing legal framework for amendments. The application was governed by s 83 of the Patents Act. The court emphasised that the Registrar’s general power to allow amendments under s 38 was inapplicable where there were pending court proceedings in which validity had been put in issue. In such circumstances, the proper route is an application under s 83. The court also noted, by way of comparison, that the UK Patents Act 1977 contains similar provisions (s 75) that extend to situations where validity could have been put in issue but was not.
On the substantive constraints, the court reiterated that the power to amend is circumscribed by s 84(3). Amendments cannot result in the specification disclosing additional matter, nor can they extend the protection conferred by the patent. The court also referred to the “base-line criteria” in s 25(5), including that claims must be clear and concise. In addition, the court recognised that even where statutory conditions are satisfied, the court retains a general discretion, guided by factors articulated in Smith Kline & French Laboratories v Evans Medical Limited.
Turning to the “futility” argument, the court addressed the logically anterior question of whether validity should be considered at the amendment stage. The court relied on Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd, where Lee Seiu Kin J had rejected an approach that effectively put the “cart before the horse” by attacking validity before the scheduled hearing of validity issues. In Ship’s Equipment, the court had held that the amendment stage should not necessarily be used to conduct a full validity trial. Applying that reasoning, the court in the present case treated the amendment decision as constrained by the statutory amendment limits and the amendment-specific criteria, rather than as a substitute for the later validity determination.
However, the court did not treat the futility argument as irrelevant. Instead, it examined the amendments through the lens of s 84(3) and the novelty/method-of-treatment issues that were directly implicated by the proposed claim format. The amendments were essentially a change from a “method of treatment” claim to a “Swiss-style” claim. In general terms, Swiss-style claims are framed as “use of compound X in the manufacture of a medicament for a specified therapeutic use Y”. This claim format is often used to navigate jurisdictions where pure method-of-treatment claims are excluded, while still capturing the therapeutic use of a known compound.
In the present case, the granted claims were framed as methods for treating pain by administering a therapeutically effective amount of a compound of Formula I (pregabalin-related chemical formula parameters) to a mammal in need of treatment. The proposed amendments sought to recast the claims so that they would be directed to the use of the compound in the manufacture of a medicament for treating specified categories of pain (for example, inflammatory pain, neuropathic pain, cancer pain, postoperative pain, and other pain types). The court therefore had to consider whether this recasting was permissible under Singapore’s patent law, and whether it complied with the prohibition on additional matter and extension of protection.
Although the extract provided does not reproduce the full detailed reasoning on each sub-issue, the structure of the judgment indicates that the court analysed (i) whether the proposed amendments would disclose additional matter; (ii) whether they would extend the protection conferred by the patent; and (iii) whether the amendments were barred by s 84(3). The court also addressed the pharmaceutical patent context, including the requirement of novelty and the “method of treatment exclusion”, and the “twin perils” of novelty and method-of-treatment exclusion when attempting to convert method claims into Swiss-style use claims.
In addition to statutory compliance, the court addressed discretion. It considered whether there was unreasonable delay in seeking the amendments, whether the plaintiff was attempting to obtain an unfair advantage from a patent it knew was invalid, and whether the plaintiff had failed to make full disclosure of relevant matters. The court’s conclusion that it should not allow the amendments suggests that, in its view, the amendments were not merely a technical correction but a strategic attempt to salvage a patent facing validity objections, particularly as the patent neared the end of its term.
What Was the Outcome?
The High Court dismissed the plaintiff’s application for leave to amend the patent claims. Practically, this meant that the plaintiff could not rely on the proposed amended claims to preserve or reshape the scope of its monopoly while the litigation proceeded.
As a result, the defendant’s counterclaim for revocation and the broader validity dispute remained the relevant battleground, without the plaintiff being able to “rewrite” the claims into a Swiss-style format through the amendment mechanism.
Why Does This Case Matter?
This decision is significant for pharmaceutical patent litigation in Singapore because it illustrates the strict boundaries on claim amendment during pending proceedings. Practitioners often seek to amend claims to address validity objections, including the method-of-treatment exclusion. However, Warner-Lambert underscores that even where Swiss-style claim formats are conceptually used to overcome method-of-treatment barriers, amendments must still satisfy the statutory constraints in s 84(3) and the court’s discretionary assessment.
For lawyers, the case is also useful for understanding how Singapore courts approach the amendment stage procedurally. The court’s reliance on Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd reflects a caution against turning amendment applications into full validity trials. Yet, the court will still scrutinise whether the amendments introduce additional matter or extend protection, and will consider novelty and related patentability concepts insofar as they bear directly on the amendment limits.
Finally, the discretionary factors—delay, fairness, and disclosure—serve as a reminder that amendment is not an automatic right. Where amendments appear to be driven by litigation strategy rather than genuine correction of claim scope, courts may be reluctant to allow them, particularly in time-sensitive contexts such as patents nearing expiry.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including:
- Section 83(1) (leave to amend patent specification)
- Section 84(3) (limits on amendments: no additional matter; no extension of protection)
- Section 25(5) (base-line criteria, including clarity and conciseness)
- Section 36 (patent term: 20 years from filing date)
- Section 38 (Registrar’s general power to amend, noted as inapplicable where court proceedings are pending and validity is in issue)
- Medicines Act (Cap 176, 1985 Rev Ed), section 12A(3)(a) (HSA product licence notification framework)
- Rules of Court, Order 87A rule 11(1) (advertisement of proposed amendments and opposition procedure)
- UK Patents Act 1977 (comparative reference to section 75)
Cases Cited
- Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd and others and another suit [2015] 4 SLR 781
- Trek Technology (Singapore) Pte Ltd v FE Global Electronics Pte Ltd and other and other suits [2005] 3 SLR(R) 389
- Smith Kline & French Laboratories v Evans Medical Limited [1989] FSR 561
- FE Global (HC) (as referenced in the extract) [2005] 3 SLR(R) 389
Source Documents
This article analyses [2016] SGHC 106 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.